Stock Market Reviews

AVBP (ArriVent BioPharma, Inc.) News

Get the latest news, insights, and market updates on AVBP (ArriVent BioPharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
  Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event just 48 hours away, you can bet the trading volume will fall off a cliff. Wednesday will be a day for the junior ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
  Dec 23, 2025 - $AVBP
• ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
  Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regulatory approvals NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today a
  Dec 22, 2025 - $AVBP
• We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Nov 12, 2025 - $AVBP
• ArriVent BioPharma Reports Third Quarter 2025 Financial Results
  Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 202
  Nov 10, 2025 - $AVBP
• ArriVent Appoints Brent S. Rice as Chief Commercial Officer
  NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. “Brent brings a proven track record in laun
  Sep 22, 2025 - $AVBP
• Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
  16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line patientsConfirmed CNS (central nervous system) responses with firmonertinib including complete responses (CRs) by BICRFirmonertinib rapidly decreased or cleared PACC circulating tumor DNA (ctDNA) in frontline patients across PACC mutation types
  Sep 9, 2025 - $AVBP
• ArriVent BioPharma Reports Second Quarter 2025 Financial Results
  Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC projected to be in early 2026Cash and investments of $254.5 million as of
  Aug 11, 2025 - $AVBP
• New Strong Sell Stocks for July 21st
  CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.
  Jul 21, 2025 - $AVBP
• ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
  Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first
  Jul 21, 2025 - $AVBP
• Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Looming Tariff Deadline
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) edged 0.03% higher and the active
  Jul 2, 2025 - $AVBP